Please login to the form below
Nightstar
This page shows the latest Nightstar news and features for those working in and with pharma, biotech and healthcare.
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture
Biogen said the new licensing deal continues its expansion into ophthalmology through the recent $800m acquisition of gene therapy specialist Nightstar Therapeutics.
Latest news
-
Biogen’s R&D chief Ehlers heads for the exit
Biogen has been directing its attention to other areas such as immunology and ophthalmology, recently acquiring Nightstar Therapeutics to add a pipeline of gene therapies for inherited retinal diseases for example,
-
Pfizer goes big on gene therapy with $500m facility spend
Just this year, for example, Roche agreed to buy Spark for $4.3bn – although it is still struggling to get the deal over the wire – while Biogen snapped up Nightstar Therapeutics
-
Syncona start-up Quell Therapeutics appoints chief exec
One investment in the field has just paid off, with gene therapy company Nightstar being sold to Biogen for $800m..
-
Syncona launches another cell therapy company, Treg specialist Quell
Another of its start-ups, gene therapy specialist Nightstar Therapeutics was bought up by Biogen earlier this year for $800m.
-
Spinraza keeps Biogen afloat as Tecfidra stalls
Ahead of that bad news, Biogen had announced its $800m takeover of gene therapy company Nightstar, which it hopes will add to its existing pipeline of rare disease therapy candidates. ... The Nightstar Therapeutics provides the firm with two potentially
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Nightstar was bought by Biogen for $800m in March.
-
European venture funding for the life science sector
The recent flotation of Syncona’s Nightstar Therapeutics demonstrates that it’s not the perception of European companies per se, but fragility in the capital markets’ infrastructure that is impeding access
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
